The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19

Journal of Clinical Psychopharmacology

Volumn 27, Issue 3, 2007, Pages 241-245

  De Leon, Jose ^a,b,c  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c EASTERN STATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIHYDROCODEINE; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; MIRTAZAPINE; NEUROLEPTIC AGENT; OMEPRAZOLE; OXYCODONE; PAROXETINE; PHENYTOIN; RISPERIDONE; TAMOXIFEN; TRAMADOL;

CLINICAL TRIAL; DNA MICROARRAY; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HOMOZYGOSITY; HUMAN; PEPTIC ULCER; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RACE DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ALLELES; ANTI-ULCER AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2D6; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHARMACOGENETICS; PHENOTYPE; PROPYLAMINES; VARIATION (GENETICS);

EID: 34248596149     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318058244d     Document Type: Editorial

References (42)

1. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-750.
2. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
3. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for using pharmacogenetic testing of CYP450 2D6 and CYP450 2C19 in psychiatry. Psychosomatics. 2006;47:75-85.
4. Johnson M, Markham-Abedi C, Susce MT, et al. A poor metabolizer for both Cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19): a case report on antidepressant treatment. CNS Spectr. 2006;11:757-760.
5. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155-163.
6. Preskorn SH. The differential effect of the serotonin selective reuptake inhibitors on the cytochrome P450 enzymes. J Psychopharmacol. 1998;12(suppl 3):S89-S97.
7. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005;25:226-229.
8. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51:73-78.
9. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993;90:11825-11829.
10. Agundez J, Ledesma M, Ladero J, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther. 1994;57:265-269.
11. de Leon J. The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006;6:277-286.
12. Lovlie R, Daly AK, Matre GE, et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics. 2001;11:45-55.
13. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
14. de Leon J, Susce MT, Pan R-M, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.
15. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262-273.
16. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1356-1358.
17. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121.
18. Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997;19:543-544.
19. de Leon J, Dinsmore L, Wedlund PJ. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers [letter]. J Clin Psychopharmacol. 2003;23:420-421.
20. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
21. Janicak PG, Davis JM, Preskorn SH, et al. Treatment with antidepressants. Therapeutic drug monitoring. In: Janicak PG, Davis JM, Preskorn SH, eds, et al. Principles and Practice of Psychopharmacotherapy. 2nd ed. Baltimore: Williams & Wilkins; 1997:306-315.
22. Wedlund PJ, de Leon J. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin Pharmacol Ther. 2004;75:373-375.
23. Anderson CB, True JE, Ereshefsky L, et al. Risperidone dose, plasma levels and response. 1993 New Research Program and Abstracts: American Psychiatric Association Annual Meeting; May 1993; San Francisco, CA. NR 217:113.
24. de Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007 (in press).
25. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129:1027-1030.
26. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153-167.
27. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44:571-590.
28. Sauer JM, Poinsler GD, Mattiuz EL. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31:98-107.
29. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(suppl 12):50-55.
30. Allen AJ, Wernicke J, Dunn D, et al. Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive vs. poor metabolizers. Biol Psychiatry. 2002;51:37S.
31. Rudberg I, Hendset M, Uthus LH, et al. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit. 2006;28:102-105.
32. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102-1109.
33. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
34. Mrazek DA. Are the 5HT transporter and/or the P450 isoenzyme genes associated with response/remission to citalopram? Biol Psychiatry. 2006;59:105S.
35. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 Genotyping Test: integrating a new clinical tool. Mol Diagn Ther. 2006;10:135-151.
36. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76-89.
37. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;6:174-185.
38. Ruaño G, Makowski G, Windemuth A, et al. Common cytochrome P450 gene mutations and high carrier prevalence in an urban tertiary care center in the USA northeast: implications for personalized drug safety. Personalized Med. 2006;3:131-137.
39. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005;102:543-549.
40. Chou WH, Yan FX, de Leon J, et al. An extension of a pilot study: impact from the cytochrome P450-2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. J Clin Psychopharmacol. 2000;20:246-251.
41. Ozdemir V, Aklillu E, Mee S, et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006;7:119-133.
42. Preskorn SH. A message from Titanic. J Pract Psychiatry Behav Health. 1998;4:236-242.